Treatment with the PD-1 antibody alone could reactivate the tumor-infiltrated CD8+ T cells in H22 tumors by increasing the proportions of IFNγ+, TNFα+ and Granzyme B+ (GZMB+) cells within the CD8+ T cell population (Fig. 7G, H). The gene discussed is CD8A; the disease is neoplasm.